Prevention of Neurosurgical Wound Infections (POWI)
Pilot Project: Prevention of Neurosurgical Wound Infections
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Oregon
-
Portland, Oregon, United States, 97239
- University Hospital, Oregon Health & Science University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- deep brain stimulators (DBS)
- spinal cord stimulators (SCS)
- motor cortex stimulators (MCS)
- vagus nerve stimulators (VNS)
- peripheral nerve stimulators (PNS)
Exclusion Criteria:
- allergies to vancomycin
- immunocompromise or taking immunosuppressant drugs
- currently taking aminoglycoside antibiotics, such as amikacin, gentamicin, neomycin, streptomycin or tobramycin
- diagnosed renal failure
- currently undergoing chemotherapy
- pregnancy
- non-english speakers
- unable to return for follow-up, or unable to be contacted by telephone
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Vancomycin
Subjects in the experimental group will receive Vancomycin injected directly into the wound pocket.
|
Subjects randomized to the vancomycin group will receive an injection (up to 10 mL) of 5 mg/mL vancomycin administered directly into the wound with a blunt needle following watertight fascial closure.
|
|
Placebo Comparator: Saline
Subjects in the saline group will receive a Saline injection directly into the wound pocket.
|
Subjects randomized to the saline group will receive an injection (up to 10 mL) of saline solution directly into the wound following watertight fascial closure.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of Infection That Requires Removal of the Neurosurgical Device
Time Frame: Six months post-operation
|
The primary outcome was infection that required removal of the implanted device within 6 months of surgery.
At our institution all patients with evidence of hardware infection have the entire stimulation/pump system removed.
Subjects were either seen in clinic or reached by telephone more than 6 months after surgery and assessed for whether they had had infection requiring hardware removal or any superficial infection requiring additional post-operative antibiotics.
|
Six months post-operation
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Kim J Burchiel, MD, Department of Neurological Surgery, Oregon Health & Science University
- Principal Investigator: Valerie C Anderson, PhD, MCR, Department of Neurological Surgery, Oregon Health & Science University
- Principal Investigator: Stephen T Magill, PhD, School of Medicine, Oregon Health & Science University
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- IRB_5170
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Surgical Wound Infections
-
NCT03716687TerminatedSurgical Wound | Surgical Site Infection | Wound Dehiscence, Surgical | Dehiscence of Internal Surgical Wound
-
NCT05716490Active, not recruitingSurgical Wound | Surgical Wound Infection | Surgical Site Infection | Surgical Wound, Healed | Surgical Complication | Surgical Wound Dehiscence | Surgical Wound Haemorrhage
-
NCT02992951CompletedSurgical Wound | Wound Infection | Surgical Incision | Infection, Bacterial | Wound Infection, Surgical
-
NCT04453319UnknownWound Infection | Wound Surgical
-
NCT02500875Unknown
-
NCT02253069CompletedSurgical Site Infections
-
NCT00260494TerminatedPostoperative Complications | Surgical Wound Infection | Surgical Wound Dehiscence
-
NCT01724255CompletedSurgical Wound Infection | Patient Satisfaction | Surgical Wound Healing
-
NCT06220344CompletedWound Infection | Wound Dehiscence | Wound Surgical | Wound Bleeding
-
NCT05977816RecruitingWound Infection | Cosmesis | Wound Surgical
Clinical Trials on Vancomycin
-
NCT01509339WithdrawnCystic Fibrosis | Methicillin-resistant Staphylococcus Aureus
-
NCT02951702CompletedClostridium Difficile Infection | Prophylaxis | Vancomycin
-
NCT07338773RecruitingDiabetic Foot Infection | Diabetic Amputation Foot Wound | Diabetic Foot Disease
-
NCT02051595Completed
-
NCT00861887WithdrawnClostridium Difficile Colitis
-
NCT04993027Not yet recruitingInfection of Total Hip Joint Prosthesis | Infection of Total Knee Joint Prosthesis
-
NCT00138112CompletedHematologic Malignancies | Streptococcal Sepsis